Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22343518 | 1.00 | MAPKAPK2 (0.31) | MAPKAPK2 | |
| SCHEMBL22325262 | 0.90 | JAK2 (0.31) | — | |
| SCHEMBL22325267 | 0.90 | JAK2 (0.31) | — | |
| SCHEMBL29657180 | 0.85 | PDPK1 (0.31) | — | |
| SCHEMBL22325278 | 0.83 | — | — | |
| SCHEMBL22325280 | 0.83 | — | — | |
| SCHEMBL28850992 | 0.82 | JAK3 (0.33) | — | |
| SCHEMBL29950366 | 0.82 | JAK3 (0.33) | — | |
| SCHEMBL22325300 | 0.82 | JAK3 (0.33) | — | |
| SCHEMBL22343494 | 0.81 | MAPKAPK2 (0.31) | MAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12325707-B2 | Process for preparing enantiomerically enriched JAK inhibitors | SUN PHARMACEUTICAL INDUSTRIES, INC. (US) | 2025-06-10 | — | — | US | disclosed |
| US-20240368166-A1 | PROCESS FOR PREPARING ENANTIOMERICALLY ENRICHED JAK INHIBITORS | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2024-11-07 | — | — | US | disclosed |
| US-20240300963-A1 | PROCESS FOR PREPARING ENANTIOMERICALLY ENRICHED JAK INHIBITORS | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2024-09-12 | — | — | US | disclosed |
| US-20220306636-A1 | PROCESS FOR PREPARING ENANTIOMERICALLY ENRICHED JAK INHIBITORS | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2022-09-29 | — | — | US | disclosed |
| US-20220213105-A1 | PROCESS FOR PREPARING ENANTIOMERICALLY ENRICHED JAK INHIBITORS | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2022-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12325707-B2 | Process for preparing enantiomerically enriched JAK inhibitors | JAK1, JAK2, JAK3 | MAPKAPK2 259/4885 |
| US-20220213105-A1 | PROCESS FOR PREPARING ENANTIOMERICALLY ENRICHED JAK INHIBITORS | JAK1, JAK2, JAK3 | MAPKAPK2 259/4885 |
| US-20240300963-A1 | PROCESS FOR PREPARING ENANTIOMERICALLY ENRICHED JAK INHIBITORS | JAK1, JAK2, JAK3 | MAPKAPK2 259/4885 |
| US-20240368166-A1 | PROCESS FOR PREPARING ENANTIOMERICALLY ENRICHED JAK INHIBITORS | JAK1, JAK2, JAK3 | MAPKAPK2 259/4885 |
| US-20220306636-A1 | PROCESS FOR PREPARING ENANTIOMERICALLY ENRICHED JAK INHIBITORS | JAK1, JAK2, JAK3 | MAPKAPK2 259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.